From: Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial
Parameter
IFN alpha-2b
IFN gamma
Cmax (pg/mL)
263 ± 129
9.3 ± 7.0
Tmax (h)
12.0 ± 6.0
6.0 ± 0.8
λ (h-1)
0.16 ± 0.06
0.07 ± 0.05
t1/2 (h)
4.9 ± 1.4
13.4 ± 27.1
AUC (pg.h/mL)
4483 ± 4485
87.5 ± 89.9
MRT (h)
13.9 ± 7.9
13.5 ± 8.2